Comparing the current results to its competitors, Pfizer Inc reported Revenue increase in the 2 quarter 2026 by 2.6 % year on year. The revenue growth was below Pfizer Inc's competitors' average revenue growth of 4.34 %, achieved in the same quarter.
Pfizer Inc, slower than the average decrease reported by the company's competitors of -66.21 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -66.21 %
Pfizer Inc's Comment on Competition and Industry Peers
The company's competitive landscape includes products with significant patent rights in the U.S., Europe, and Japan. Key products and their patent expiration years are as follows: Xeljanz (2026-2029), Prevnar 13/Prevenar 13 (2027-2028), Adcetris (2025-2027), Eliquis (2026-2028), Ibrance (2027-2029), Xtandi (2027-2028), Vyndaqel/Vyndamax/Vynmac (2027-2029), and Xalkori (2027-2028). These patents are relevant to the company's business and its competition with products sold by competitors, including Pfizer Inc.
April 24, 2025
In an exciting and promising announcement, Pfizer Inc. (NYSE: PFE) has spotlighted its latest advancements in oncology at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled from May 30 to June 3 in Chicago, Pfizer will present data from more than 60 research abstracts, including 9 oral and 6 rapid oral presentations that delve into their innovative cancer medicines. This comprehensive showcase will highlight Pfizers commitment to redefining cancer care through cutting-edge treatments across key tumor areas like breast and genitourinary cancers.However, the road to innovation is not without its challenges. Recently, Pfizer faced setbacks with its goal of penetrating the ...
April 17, 2025
Pfizer s ABRYSVO RSV Vaccine Receives Expansive ACIP Recommendation for Adults 50-59 In a significant move towards strengthening respiratory healthcare, Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has extended its recommendation for Pfizer s respiratory syncytial virus (RSV) vaccine, ABRYSVO, to include adults aged 50-59 at increased risk of RSV-associated lower respiratory tract disease (LRTD). This strategic decision aims to enhance protection for a vulnerable demographic, potentially curbing the impact of RSV-related complications. RSV is a common respiratory virus that poses severe health risks, ...
January 6, 2025
Pfizer s Upcoming Presentation at J.P. Morgan Healthcare Conference Highlights Engagement with Investors Pfizer Inc. (NYSE: PFE), one of the world s premier biopharmaceutical companies, has announced an opportunity for investors and the general public to view and listen to a webcast featuring a discussion with Albert Bourla, Pfizer s Chairman and Chief Executive Officer. This event will take place at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. Pacific Standard Time (PST), underscoring Pfizer s proactive approach in engaging with its stakeholders and the broader healthcare community.The J.P. Morgan Healthcare Conference, a key event within the pharmaceutical and healthc...
December 21, 2024
for CSIMarket.com Recent announcements from Pfizer Inc. have highlighted significant advancements in the treatment of two severe medical conditions: metastatic colorectal cancer (mCRC) and severe hemophilia A or B. The U.S. Food and Drug Administration (FDA) and the European Commission (EC) have granted approvals for two medications: BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for cancer treatment, and HYMPAVZI (marstacimab) for hemophilia management. BRAFTOVI: A New Option for Metastatic Colorectal Cancer The FDA has approved BRAFTOVI in combination with cetuximab (marketed as ERBITUX) and a chemotherapy regimen known as mFOLFOX6. This treatment is designated for patients diagnosed...
December 20, 2024
In a significant advancement for cancer therapy, the U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s BRAFTOVI (encorafenib) as a combination treatment alongside cetuximab (marketed as ERBITUX) and mFOLFOX6 (a regimen of fluorouracil, leucovorin, and oxaliplatin) for patients suffering from metastatic colorectal cancer (mCRC) with the BRAF V600E mutation. This approval marks a pivotal moment for patients with this aggressive cancer, as BRAFTOVI targets a specific genetic mutation that afflicts a subset of colorectal cancer patients.The approval is based on evidence demonstrating a statistically significant and clinically meaningful improvement in patient outcomes when treated with the new...
November 20, 2024
Pfizer s HYMPAVZI (Marstacimab): A Milestone in Hemophilia Treatment Amid Global Approvals In a significant breakthrough for the management of severe hemophilia, Pfizer Inc. has garnered dual regulatory approvals for HYMPAVZI (marstacimab), marking a pivotal advancement in therapeutic options for patients suffering from this complex coagulation disorder. The European Commission (EC) has granted marketing authorization for HYMPAVZI for use in adults and adolescents aged 12 years and older who weigh at least 35 kilograms and have severe hemophilia A or B without the presence of specific inhibitors. This follows the recent approval by the U.S. Food and Drug Administration (FDA), signifying a robust endorsement ...
October 12, 2024
In a significant advancement for the management of hemophilia, the U.S. Food and Drug Administration (FDA) has officially granted approval for Pfizer Inc. s HYMPAVZI (marstacimab-hncq). This new therapeutic agent is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents aged 12 years and older diagnosed with hemophilia A or B, specifically in patients who do not have inhibitors to factor VIII or factor IX.Hemophilia A, caused by a deficiency in factor VIII, and hemophilia B, stemming from a deficiency in factor IX, are both inherited bleeding disorders that can lead to serious complications if not managed effectively. The absence of inhibitors pres...
September 25, 2024
In a significant move within the biopharmaceutical industry, Pfizer Inc. (NYSE: PFE) has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) aimed at treating sickle cell disease (SCD) from worldwide markets. This decision not only casts a shadow on the once-promising treatment for SCD but also highlights the complexities of drug efficacy and safety assessments in clinical practice. Concurrently, Pfizer is halting all active voxelotor clinical trials and related expanded access programs globally. This decision is based on a comprehensive review of clinical data, which indicated that the overall benefits of OXBRYTA no longer outweigh the associated risks in patients with sickle cell disease....
September 11, 2024
At the European Society for Medical Oncology (ESMO) Congress 2024 held in Barcelona from September 13-17, Pfizer Inc. (NYSE: PFE) is showcasing its formidable portfolio in oncology, underscoring the company s commitment to innovation and the development of next-generation therapies. The event highlights the unveiling of new research and combination treatment approaches that have the potential to reshape clinical practice in oncology, as demonstrated by over 50 company-sponsored, investigator-sponsored, and collaborative research abstracts slated for presentation. Among these are more than 10 targeted oral and mini-oral sessions that promise to capture the attention of healthcare professionals and investors a...
September 3, 2024
Advances in Vaccine Development: Positive Phase 2 Booster Results for Lyme Disease Candidate and European Approvals of Pneumococcal and Ulcerative Colitis Therapies The biopharmaceutical landscape continues to evolve with significant developments in vaccine and therapeutic interventions. Valneva SE and Pfizer Inc. have reported positive Phase 2 booster results for their Lyme disease vaccine candidate, VLA15, signifying advancement in combating this prevalent vector-borne disease. Concurrently, Pfizer has achieved European Commission approvals for PREVENAR 20, a 20-valent pneumococcal conjugate vaccine, and VELSIPITY (etrasimod), a treatment for moderately to severely active ulcerative colitis. These strides...
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Evofem Biosciences Inc's business model focuses on the development and commercialization of innovative products in the women's sexual and reproductive health sector.
180 Life Sciences Corp is a biotechnology company engaged in the research and development of novel drugs that target inflammation and fibrosis to address various diseases such as fibrosis, inflammation, and pain.
Sources:
Pfizer Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pfizer Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
